Kevzara
E579611
Kevzara is a prescription monoclonal antibody medication (sarilumab) used to treat adults with moderate to severe rheumatoid arthritis by targeting the interleukin-6 (IL-6) receptor.
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
biologic disease-modifying antirheumatic drug
ⓘ
monoclonal antibody ⓘ pharmaceutical drug ⓘ |
| actsOn | cytokine signaling pathway ⓘ |
| approvalYear | 2017 ⓘ |
| approvedBy | U.S. Food and Drug Administration NERFINISHED ⓘ |
| ATCCode | L04AC14 ⓘ |
| belongsToRegimen | chronic long-term therapy for rheumatoid arthritis ⓘ |
| canBeUsedAs | monotherapy for rheumatoid arthritis ⓘ |
| canBeUsedWith | methotrexate ⓘ |
| contraindicatedIn | patients with active serious infections ⓘ |
| developedBy |
Regeneron Pharmaceuticals
NERFINISHED
ⓘ
Sanofi NERFINISHED ⓘ |
| dosageForm |
prefilled pen
ⓘ
prefilled syringe ⓘ |
| formulation | solution for injection ⓘ |
| hasActiveIngredient | sarilumab NERFINISHED ⓘ |
| hasBlackBoxWarning | risk of serious infections ⓘ |
| hasDrugClass |
immunosuppressive agent
ⓘ
interleukin-6 receptor antagonist ⓘ |
| hasGenericName | sarilumab NERFINISHED ⓘ |
| hasMolecularTarget | IL6R NERFINISHED ⓘ |
| hasTradeName | Kevzara NERFINISHED ⓘ |
| indicatedFor |
moderate rheumatoid arthritis in adults
ⓘ
severe rheumatoid arthritis in adults ⓘ |
| indicatedPopulation | adult patients ⓘ |
| inhibits | IL-6 receptor signaling ⓘ |
| isAdministered | every two weeks in many regimens ⓘ |
| isHumanized | true ⓘ |
| isMarketedIn |
European Union
NERFINISHED
ⓘ
United States NERFINISHED ⓘ |
| legalStatus | prescription-only medicine ⓘ |
| mayCause |
elevated liver enzymes
ⓘ
injection site reactions ⓘ neutropenia ⓘ |
| mechanismOfAction | blocks binding of IL-6 to its receptor ⓘ |
| monoclonalAntibodyType | human monoclonal antibody ⓘ |
| reduces |
inflammation associated with rheumatoid arthritis
ⓘ
joint pain ⓘ joint swelling ⓘ |
| regulates | immune response ⓘ |
| requiresMonitoringOf |
lipid profile
ⓘ
liver function tests ⓘ neutrophil counts ⓘ |
| routeOfAdministration | subcutaneous injection ⓘ |
| targets | interleukin-6 receptor ⓘ |
| treats | rheumatoid arthritis ⓘ |
| usedAs | second-line therapy after inadequate response to other DMARDs ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.